WELCOME TO OUR PARKINSON'S PLACE!

I HAVE PARKINSON'S DISEASES AND THOUGHT IT WOULD BE NICE TO HAVE A PLACE WHERE THE CONTENTS OF UPDATED NEWS IS FOUND IN ONE PLACE. THAT IS WHY I BEGAN THIS BLOG.

I COPY NEWS ARTICLES PERTAINING TO RESEARCH, NEWS AND INFORMATION FOR PARKINSON'S DISEASE, DEMENTIA, THE BRAIN, DEPRESSION AND PARKINSON'S WITH DYSTONIA. I ALSO POST ABOUT FUNDRAISING FOR PARKINSON'S DISEASE AND EVENTS. I TRY TO BE UP-TO-DATE AS POSSIBLE.

I AM NOT RESPONSIBLE FOR IT'S CONTENTS. I AM JUST A COPIER OF INFORMATION SEARCHED ON THE COMPUTER. PLEASE UNDERSTAND THE COPIES ARE JUST THAT, COPIES AND AT TIMES, I AM UNABLE TO ENLARGE THE WORDING OR KEEP IT UNIFORMED AS I WISH. IT IS IMPORTANT TO UNDERSTAND I AM A PERSON WITH PARKINSON'S DISEASE. I HAVE NO MEDICAL EDUCATION,

I JUST WANT TO SHARE WITH YOU WHAT I READ ON THE INTERNET. IT IS UP TO YOU TO DECIDE WHETHER TO READ IT AND TALK IT OVER WITH YOUR DOCTOR. I AM JUST THE COPIER OF DOCUMENTS FROM THE COMPUTER. I DO NOT HAVE PROOF OF FACT OR FICTION OF THE ARTICLE. I ALSO TRY TO PLACE A LINK AT THE BOTTOM OF EACH ARTICLE TO SHOW WHERE I RECEIVED THE INFORMATION SO THAT YOU MAY WANT TO VISIT THEIR SITE.

THIS IS FOR YOU TO READ AND TO ALWAYS KEEP AN OPEN MIND.

PLEASE DISCUSS THIS WITH YOUR DOCTOR, SHOULD YOU HAVE ANY QUESTIONS, OR CONCERNS. NEVER DO ANYTHING WITHOUT TALKING TO YOUR DOCTOR FIRST..

I DO NOT MAKE ANY MONEY FROM THIS WEBSITE. I VOLUNTEER MY TIME TO HELP ALL OF US TO BE INFORMED.

I WILL NOT ACCEPT ANY ADVERTISEMENT OR HEALING POWERS, HEALING FROM HERBS AND ETC. UNLESS IT HAS GONE THROUGH TRIALS AND APPROVED BY FDA. IT WILL GO INTO SPAM.

THIS IS A FREE SITE FOR ALL WITH NO ADVERTISEMENTS

THANK YOU FOR VISITING! TOGETHER WE CAN MAKE A DIFFERENCE!

TRANSLATE

Thursday, May 17, 2018

Parkinson’s Researchers Unravel How Toxic Alfa-synuclein Affects Memory Nerve Cells

MAY 17, 2018 BY MARTA FIGUEIREDO 



Scientists are closer to understanding how toxic alpha-synuclein (α-syn) aggregates affect the nerve cells involved in memory, which may point to new therapeutic strategies to prevent the development of cognitive dysfunction in Parkinson’s and Lewy body dementias.
Alpha-synuclein accumulation – eventually leading to nerve cell death – is a hallmark of Parkinson’s disease and dementia with Lewy bodies. Changes in nerve cell activity have been associated with the development of different forms of dementia, and shown to precede nerve cell damage in neurodegenerative diseases such as Alzheimer’s disease.
While the effects of alpha-synuclein aggregates in dopamine nerve cells of the brain region involved in motor function has been studied extensively, its effects in other type of brain neurons, such as those located in the hippocampus – a brain region that plays a key role in memory formation – is unknown.
To understand what happens in hippocampal nerve cells when alpha-synuclein aggregates start to form – before cell death – researchers at the University of Alabama School of Medicine and Yale University used a model to generate alpha-synuclein aggregates in mouse nerve cells.
The model – previously developed by researchers at the University of Pennsylvania, including Laura Volpicelli-Daley, PhD, the current study’s co-senior author – consists of two steps.
The first step is the generation of alpha-synuclein fibrils from synthetic alpha-synuclein molecules, by putting them in a test tube and shaking it for several days. Next, mouse nerve cells in culture are exposed to the pre-formed fibrils, which are internalized and induce the recruitment of soluble alpha-synuclein to form aggregates that resemble the toxic, insoluble aggregates found in Parkinson’s and dementia with Lewy bodies.
With time, the formation and accumulation of toxic alpha-synuclein aggregates starts to impair nerve cell function, ultimately leading to cell death. All these features make this a good model to study aggregate formation, its impact on nerve cell function, and the development of potential therapeutics.
Researchers investigated what happens in the synapse of hippocampal nerve cells seven days after exposure to alpha-synuclein fibrils, when cell death is not yet present. The synapse is the contact site between nerve cells where an electrical or chemical signal is transmitted from one nerve cell (presynaptic) to another (postsynaptic).
The formation of alpha-synuclein aggregates led to structural and functional changes in these nerve cells, including increased presynaptic activity, reduced postsynaptic activity – through the loss of specific cell protrusions that receive signals from the synapse – and reduced calcium levels, which are essential for signal transmission.
According to researchers, nerve cells appear to be adapting to these changes to prevent abnormally high nerve activation, by reducing the ability of a cell to receive signals from another cell that has increased activity.
These nerve cell alterations may be crucial in the development of dementia and cognitive dysfunction in Parkinson’s and dementia with Lewy bodies. And because they occur before neurodegeneration, it is possible that these cells can be rescued before they die.
“The next step will be looking at how alpha-synuclein increases presynaptic activity and whether this is a loss of alpha-synuclein function in this neuron [nerve cell] compartment or it is caused by formation of toxic alpha-synuclein aggregates,” Volpicelli-Daley said in a press release.
The researchers noted that their work supports the need to develop tools “to detect and remove abnormal α-syn at early stages of disease development,” and that by the time toxic alpha-synuclein forms aggregates, it is possible “the pathway toward neurodegeneration cannot be reversed,” they wrote.
https://parkinsonsnewstoday.com/2018/05/17/parkinsons-researchers-find-toxic-alpha-synuclein-affects-memory-cells/

No comments:

Post a Comment